Loading clinical trials...
Loading clinical trials...
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Lexicon Pharmaceuticals
NCT07481422 · Irritable Bowel Syndrome (IBS)
NCT05740319 · Irritable Bowel Syndrome
NCT05730491 · Irritable Bowel Syndrome, Abdominal Pain
NCT07089420 · IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, and more
NCT06866106 · Irritable Bowel Syndrome
Genova Clinical Research
Tucson, Arizona
Arkansas Gastroenterology
Sherwood, Arkansas
Advanced Clinical Research Institute
Anaheim, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions